FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Lucid Diagnostics Inc. Stock AnalysisComprehensive stock analysis for Lucid Diagnostics Inc. (LUCD) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisLUCD
LUCD
Lucid Diagnostics Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
LUCD
Home🔹Stocks🔹Lucid Diagnostics Inc.

Lucid Diagnostics Inc.

LUCD•NASDAQ

Lucid Diagnostics Inc.

LUCD•NASDAQ
Market cap
$93.55M
Sentiment

Your view on LUCD

Mkt Cap
$93.55M
Sentiment
Your view
LUCD
Lucid Diagnostics Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
LUCD
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Lucid Diagnostics Inc.

Industry
Medical - Devices
Sector
Healthcare
CEO
Lishan Aklog
Headquarters
One Grand Central Place, New York City, NY, US
Industry
Medical - Devices
Sector
Healthcare
CEO
Lishan Aklog
Headquarters
One Grand Central Place, New York City, NY, US
Description

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News